You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Advance Early Detection of Lupus Nephritis with ClearGold
SBC: CLEARNANO INC Topic: 400SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Accelerate Adoption of Galaxy Pro in the Biomedical Research Marketplace
SBC: GalaxyWorks LLC Topic: NHGRIProject Summary Galactic Core LLC aims to develop a robust, scalable, and managed service for performing enterprise-grade biomedical data analysis. The service will be based on the popular open-source Galaxy application (https://galaxyproject.org/), offering unlimited data storage and compute capabilities with an extremely powerful, flexible, and collaborative environment for analyzing data. ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Direct-read monitor for airborne viral pathogens
SBC: AEROSOL DEVICES INC Topic: NIAIDAerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Aptamer-based Glycomics Tools
SBC: ECHELON BIOSCIENCES, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Protein glycosylation plays very important roles in biological processes. However, detecting and differentiating such modifications rapidly is not a trivial issue. Therefore, developing novel tools that allow for the rapid detection of glycosylation patterns is of tremendous importance to the field of glycomics. In this application, we propose to develop a nove ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Automated Dynamic Lists for Efficient Electronic Health Record Management
SBC: Clinacuity, Inc Topic: NCIDESCRIPTION (provided by APPLICANT): Medical errors are recognized as the cause of numerous deaths, and even if some are difficult to avoid, many are preventable. Computerized physician order-entry systems with decision support have been proposed to reducethis risk of medication errors, but these systems rely on structured and coded information in the electronic health record (EHR). Unfortunately, ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants
SBC: BB MEDICAL SURGICAL, INC. Topic: NICHDPROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Identification and Validation of Targets of Phenotypic High Throughput Screening
SBC: COLLABORATIVE DRUG DISCOVERY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIAMSProgressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing
SBC: Bondwell Technologies Inc. Topic: 400Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health